ARQT
Arcutis Biotherapeutics, Inc.
$25.08
-1.07%
2026-08-21
About Arcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
Key Fundamentals
P/E Ratio
119.05
Forward P/E
20.09
EPS (TTM)
$0.22
ROE
15.9%
Revenue Growth (YoY)
59.3%
Profit Margin
6.1%
Debt/Equity
51.74
Price/Book
14.91
Beta
1.53
Market Cap
$3.29B
Avg Volume (10D)
1.9M
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$29.84
60D Low
$20.48
Avg Volume
1.6M
Latest Close
$25.08
Get breakout alerts for ARQT
Sign up for Breakout Scanner to receive daily notifications when ARQT triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial.
Arcutis Biotherapeutics, Inc. (ARQT) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors ARQT daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. ARQT operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.